CN111544501A - Traditional Chinese medicine for treating cerebral arterial thrombosis and application - Google Patents
Traditional Chinese medicine for treating cerebral arterial thrombosis and application Download PDFInfo
- Publication number
- CN111544501A CN111544501A CN202010445451.1A CN202010445451A CN111544501A CN 111544501 A CN111544501 A CN 111544501A CN 202010445451 A CN202010445451 A CN 202010445451A CN 111544501 A CN111544501 A CN 111544501A
- Authority
- CN
- China
- Prior art keywords
- leech
- traditional chinese
- chinese medicine
- ischemic stroke
- scalding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8884—Arisaema, e.g. Jack in the pulpit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine for treating cerebral arterial thrombosis and application thereof. The invention relates to a traditional Chinese medicine for treating ischemic stroke, which is prepared from three selected Chinese herbal medicine raw materials of leech, ligusticum wallichii and arisaema cum bile according to the parts by weight, wherein: leech: ligusticum wallichii: arisaema cum bile = (10-15): (1-3): (0.5-1.5). The invention adopts pure traditional Chinese medicine formula, accumulates abundant experience of clinical practical application, and forms a prescription through strict traditional Chinese medicine quality screening and scientific processing, so that the purposes of raw material lean and good treatment effect are achieved. The traditional Chinese medicine composition has sufficient raw material sources, no precious and fine medicinal materials, simple, safe and controllable preparation process, is one of the first-choice medicines for treating ischemic stroke patients, and has the total effective rate of the treatment effect as high as 96.7 percent.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine for treating cerebral arterial thrombosis and application thereof.
Background
Ischemic stroke, called cerebral stroke in traditional Chinese medicine, belongs to one of cardiovascular and cerebrovascular diseases. According to the statistics of medical data, the following steps are shown: the stroke has three characteristics of high morbidity, high mortality and high disability rate, and is one of diseases seriously harming the health of people. At present, 700 more than ten thousand patients with cerebral apoplexy exist in China, and more than 70 percent of the patients with cerebral apoplexy are ischemic cerebral apoplexy. The prevention and treatment of ischemic stroke is being researched urgently all over the world, and solving the problem has become a focus of the world.
Cerebral apoplexy is caused by brain tissue necrosis and softening caused by cerebral blood supply disorder, ischemia and anoxia, and mainly comprises cerebral hemorrhage, cerebral thrombosis, cerebral embolism, transient ischemic attack and the like, which are the same as those of the traditional Chinese medicine. The disease is mainly manifested by yin-yang imbalance, visceral qi imbalance, qi and blood disorder, and paroxysmal pain or sudden syncope, facial distortion, hemiplegia, etc. after chest and back, which are caused by life factors such as anxiety, anger, improper diet, etc., and is often seen in the middle-aged and the elderly. After thrombolysis, patients with ischemic stroke have two kinds of pathological changes, namely ischemia-reperfusion injury. That is, when an infarction occurs, the brain tissue is damaged by ischemia and hypoxia; after recanalization of the blood flow, the condition is sometimes not relieved but rather worsened.
This injury is referred to in basic medicine as "reperfusion injury". Therefore, the study of cerebral ischemia-reperfusion injury has become an important research direction for ischemic stroke in the medical field in recent years.
The applicant of the invention patent CN03107815.X proposed by 3/17/2003 is an oral liquid prepared from hirudo nipponia for treating cerebral hemorrhage, which is a medicament for treating the above-mentioned diseases. The oral liquid for treating cerebral hemorrhage is prepared from leeches: pseudo-ginseng: the invention relates to a Chinese medicinal composition for treating cerebral hemorrhage, which is prepared from rhubarb horsetails by mixing, disintegrating and activating blood circulation; the medicine can lead the absorption time of hematoma to be advanced, the daily blood absorption amount is obviously higher than that of patients who do not take the medicine, the effect of the medicine on patients entering ventricles of brain is very good, the medicine is particularly suitable for the acute stage of cerebral hemorrhage, the curative effect is high, the medicine effect is definite, the damage to nerve function is small, the recovery of nerve function is promoted, the death rate is reduced, and the total effective rate of treatment reaches more than 95 percent, so the medicine has very important significance for treating cerebral hemorrhage.
The invention patent CN03107816.8 proposed by the applicant on 3/17/2003 is a honeyed pill for treating thrombosis and a preparation method thereof, and is also a medicament for treating the above diseases. It is prepared from pit viper: earthworm: red sage root: ligusticum wallichii: chinese angelica: ginseng: astragalus root: safflower: caulis spatholobi: turmeric root-tuber: three-edge: hawthorn fruit: the gastrodia elata is prepared from the following components. The invention applies the theory of combining traditional Chinese medicine and western medicine, screens the medicine aiming at the treatment of the thrombus disease in modern medicine, thereby having better curative effect, being superior to various medicines for resisting the thrombus disease in the prior art, having no toxic or side effect and easily obtaining materials. It has good effect on blood fat and blood rheology, so it has important significance for treating angiopathy caused by arteriosclerosis. The invention has 97% of total effective rate on cerebral thrombosis, 93.5% of total effective rate on angiitis, and obvious improvement on blood fat and hemorheology indexes.
Although the prior art has a certain treatment effect on the diseases, medical personnel also find that the diseases have certain defects in the formula and years of clinical practice, and the treatment effect of patients with cerebral ischemia-reperfusion injury cannot reach a satisfactory degree at present.
Disclosure of Invention
Aiming at the defects and the improvement requirements in the prior art, the invention provides a traditional Chinese medicine for treating ischemic stroke and application thereof. The aim is to further improve the curative effect of treating the cerebral ischemia-reperfusion injury patient.
The invention is realized by the following technical scheme:
the traditional Chinese medicine for treating ischemic stroke comprises the following raw materials in parts by weight:
leech: ligusticum wallichii: arisaema cum bile (10-15): (1-3): (0.5-1.5).
The traditional Chinese medicine for treating ischemic stroke is prepared from the following raw materials in parts by weight:
leech: ligusticum wallichii: arisaema cum bile 12: 2: 1.
the traditional Chinese medicine for treating ischemic stroke is prepared from the following raw materials in parts by weight:
leech: ligusticum wallichii: bile arisaema ═ 10: 3: 1.5.
the traditional Chinese medicine for treating ischemic stroke is prepared from the following raw materials in parts by weight:
leech: ligusticum wallichii: arisaema cum bile 15: 1: 0.5.
the preparation method of the traditional Chinese medicine for treating ischemic stroke comprises the following steps:
step 1, taking the raw material leech according to the weight part ratio, cleaning, scalding, crushing and sieving for later use;
the leech scalding process comprises the following steps: placing pulvis Talci in a pan, parching with strong fire at 150-200 deg.C for 8-10min to flexible state, adding Hirudo, stirring, scalding at 150-200 deg.C for 5-10min, taking out when slightly bulging, sieving to remove pulvis Talci, and cooling;
step 2, taking the raw material of the ligusticum wallichii according to the weight part ratio, crushing, and sieving by a 80-200 mesh sieve for later use;
step 3, taking the raw material arisaema cum bile according to the weight part ratio, crushing, and sieving by a 80-200 mesh sieve for later use;
step 4, mixing the raw material powder obtained in the steps 1-3 according to the ratio of (10-15): (1-3): (0.5-1.5), sieving, granulating, drying, grading, and making into capsule.
The leech scalding process comprises the following steps: firstly, scalding Hirudo at 170 deg.C for 8min, and pulverizing with rhizoma Ligustici Chuanxiong and rhizoma arisaematis cum bile into fine powder; and then taking the raw material medicinal powder of 12 parts of the scalding leech, 2 parts of the ligusticum wallichii and 1 part of the arisaema cum bile according to the weight part ratio, granulating, drying, finishing granules and filling into capsules to obtain the medicine.
The leech scalding process comprises the following steps: firstly, scalding leech into a qualified product, and crushing the qualified product and the other two medicines into fine powder; and then taking 10 parts of leech, 3 parts of ligusticum wallichii and 1.5 parts of arisaema cum bile according to the weight part ratio, granulating, drying, finishing granules and encapsulating to obtain the capsule.
The leech scalding process comprises the following steps: firstly, scalding leech into a qualified product, and crushing the qualified product and the other two medicines into fine powder; taking raw material medicinal powder of 15 parts of scalding leech, 1 part of ligusticum wallichii and 0.5 part of arisaema cum bile according to the weight part ratio, granulating, drying, finishing granules and filling into capsules to obtain the medicine.
A Chinese medicinal composition for treating ischemic stroke is used for treating ischemic stroke.
A Chinese medicinal composition for treating ischemic stroke is used for treating cerebral ischemia reperfusion injury.
The invention has the following advantages and beneficial effects:
the invention is based on the theory of traditional Chinese medicine, accumulates abundant experience of clinical practical application, adopts a pure traditional Chinese medicine formula, consists of three traditional Chinese medicines of ligusticum wallichii, leech and arisaema cum bile, takes the causes of ischemic stroke, namely qi, fire, phlegm and stasis as the entry points, and takes the fundamental treatment rules of blood breaking, stasis removing, qi promoting, blood activating, heat clearing, phlegm removing and collaterals dredging as the key points. The clinical manifestations are mostly deficiency of origin and excess of superficiality, and the treatment is based on both standard and standard, namely tonifying qi, activating blood circulation, removing stasis and reducing phlegm. The invention forms a prescription through strict Chinese medicine quality screening, and achieves the purposes of lean raw materials and good treatment effect through scientific processing.
Compared with the prior art, the traditional Chinese medicine preparation has the beneficial effects that the traditional Chinese medicine preparation belongs to a pure traditional Chinese medicine preparation, the three raw materials are sufficient in source, precious and fine medicinal materials are not used, the preparation process is simple, safe and controllable, the curative effect of the medicine is obvious, the medicine is easy to take and popularize, and the traditional Chinese medicine preparation is one of preferred medicines for treating patients with ischemic stroke.
The invention has the total effective rate of more than 96.7 percent aiming at the treatment effect of the cerebral ischemia-reperfusion injury patient, and is obviously improved compared with the prior art. On the basis of the two original patent technologies, the invention is further refined, reduced and further improved by combining clinical practice medical records and practical experience for many years, so that the treatment effect on the cerebral ischemia-reperfusion injury patient is further accurately and remarkably improved. The whole formula of the invention only comprises three traditional Chinese medicines of rhizoma ligustici wallichii, leech and arisaema cum bile, wherein the leech is used for breaking blood and removing stasis, the rhizoma ligustici wallichii is used for promoting qi and activating blood circulation, and the arisaema cum bile is used for clearing heat and reducing phlegm, and is one of the first-choice medicines for patients with ischemic stroke. The medicine of the invention can greatly improve the cure rate of the cerebral ischemia reperfusion injury patient, and remarkably improve the life quality and the post-cure efficiency of the cerebral ischemia reperfusion injury patient.
The three medicines are combined, and the traditional Chinese medicine composition has the effects of promoting blood circulation to remove blood stasis, reducing phlegm and dredging collaterals. The traditional Chinese medicine composition has obvious curative effects on symptoms of palpitation, shortness of breath, dizziness, headache, lassitude, hypodynamia, tinnitus, dim eyesight, limb numbness, insomnia, amnesia and the like of a cerebral apoplexy patient, has extremely important clinical significance on the treatment of ischemic cerebral apoplexy, and is expected to provide a new research idea for the research and development of anti-ischemic cerebral apoplexy medicines.
Drawings
FIG. 1 is a flow chart of the preparation process of the present invention.
Detailed Description
The invention may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. It is specifically intended that the following description be regarded as illustrative in nature and not as restrictive in any way, since it is intended to limit the disclosure to the precise form disclosed and illustrated.
Example 1
The invention relates to a traditional Chinese medicine for treating ischemic stroke, which is prepared from three selected Chinese herbal medicine raw materials of leech, ligusticum wallichii and arisaema cum bile according to the parts by weight, wherein:
leech: ligusticum wallichii: arisaema cum bile (10-15): (1-3): (0.5-1.5).
A method for preparing traditional Chinese medicine for treating ischemic cerebral apoplexy is shown in figure 1, collecting Hirudo, rhizoma Ligustici Chuanxiong, and Arisaema cum bile at above weight parts, scalding Hirudo, pulverizing with the rest two medicines into fine powder, sieving with 80-200 mesh sieve, mixing well, granulating, drying, grading, and encapsulating to obtain the final product. The specific operation steps are as follows:
step 1, taking the raw material leech according to the weight part ratio, cleaning, scalding, crushing and sieving for later use.
The leech scalding process comprises the following steps:
placing pulvis Talci in a pan, parching with strong fire to flexible state at 150 deg.C-200 deg.C for 8-10min, adding Hirudo, stirring, heating to slightly bulging temperature at 150 deg.C-200 deg.C for 5-10min, taking out, sieving to remove pulvis Talci, and cooling.
And 2, taking the raw material of the ligusticum wallichii according to the weight part ratio, crushing, and sieving by a 80-200 mesh sieve for later use.
And 3, taking the raw material arisaema cum bile according to the weight part ratio, crushing, and sieving by a 80-200 mesh sieve for later use.
Step 4, mixing the raw material powder obtained in the steps 1-3 according to the ratio of (10-15): (1-3): (0.5-1.5), sieving, granulating, drying, grading, and making into capsule.
The traditional Chinese medicine composition has the effects of promoting blood circulation to remove blood stasis, reducing phlegm and dredging collaterals, and nourishing the heart and soothing the nerves, and has a remarkable curative effect on the recovery period of patients with ischemic stroke.
The finished medicine of the invention can be prepared into other forms of medicines, such as tablets or liquid-phase medicines, besides capsules, and is within the implementation scope of the invention.
Example 2
The invention relates to a traditional Chinese medicine for treating ischemic stroke, which is prepared from three selected Chinese herbal medicine raw materials of leech, ligusticum wallichii and arisaema cum bile according to the parts by weight, wherein: leech: ligusticum wallichii: arisaema cum bile 12: 2: 1.
A preparation method of a traditional Chinese medicine for treating ischemic stroke comprises the specific operation steps of as described in example 1, scalding Hirudo for 170 deg.C for 8min, and pulverizing the Hirudo and the other two medicines into fine powder; and then taking the raw material medicinal powder of 12 parts of the scalding leech, 2 parts of the ligusticum wallichii and 1 part of the arisaema cum bile according to the weight part ratio, granulating, drying, finishing granules and filling into capsules to obtain the medicine.
Example 3
The invention relates to a traditional Chinese medicine for treating ischemic stroke, which is prepared from three selected Chinese herbal medicine raw materials of leech, ligusticum wallichii and arisaema cum bile according to the parts by weight, wherein:
leech: ligusticum wallichii: bile arisaema ═ 10: 3: 1.5.
a preparation method of a traditional Chinese medicine for treating ischemic stroke comprises the specific operation steps of as described in example 1, scalding Hirudo into qualified product, and pulverizing the qualified product and the other two medicines into fine powder; taking the raw material medicinal powder of 10 parts of the scalding leech, 3 parts of the ligusticum wallichii and 1.5 parts of the arisaema cum bile according to the weight part ratio, granulating, drying, finishing granules and filling into capsules to obtain the medicine.
Example 4
The invention relates to a traditional Chinese medicine for treating ischemic stroke, which is prepared from three selected Chinese herbal medicine raw materials of leech, ligusticum wallichii and arisaema cum bile according to the parts by weight, wherein:
leech: ligusticum wallichii: arisaema cum bile 15: 1: 0.5.
a preparation method of a traditional Chinese medicine for treating ischemic stroke comprises the specific operation steps of as described in example 1, scalding Hirudo into qualified product, and pulverizing the qualified product and the other two medicines into fine powder; taking raw material medicinal powder of 15 parts of scalding leech, 1 part of ligusticum wallichii and 0.5 part of arisaema cum bile according to the weight part ratio, granulating, drying, finishing granules and filling into capsules to obtain the medicine.
Example 5
And 60 patients in stroke recovery stage with wind-phlegm obstruction type stroke meeting the relevant standards are selected for hospitalization in stroke areas of 6-10 months in 2017. Patients were divided into treatment 1 and treatment 2 groups, 30 cases each, according to the order of admission. The general data comparison between two groups of patients shows that the difference is not statistically significant (P >0.05) and is comparable, see Table 1.
TABLE 1 general data comparison of two groups of patients (
N)
Note: the two sets of the data are compared with each other,*P>0.05 indicated significant differences.
Diagnostic criteria: the relevant diagnosis is carried out according to Chinese guidelines for acute ischemic cerebral apoplexy and Chinese State administration of traditional Chinese medicine, cooperative group of brain diseases and acute symptoms, standards of apoplexy diagnosis and treatment effect evaluation (trial), and the like.
Inclusion criteria were:
firstly, the patient is in a wind-phlegm obstruction type according with the diagnosis standard, and the disease attack time is 14-30 days;
② the age of 35-75 years old;
③ patients without serious cardiovascular, respiratory, immune, blood and other system diseases and malignant tumors;
fourthly, the patient has clear mind without mental disorder;
the liver and kidney function examination is abnormal;
and sixthly, the patients or the family members voluntarily agree to participate in the observation.
Exclusion criteria:
not meeting the diagnosis standard and Transient Ischemic Attack (TIA) or hemorrhagic patients;
② surgical operation treatment is carried out in the last half year;
③ less than or equal to 1 grade of muscle strength of the patient;
fourthly, the disease is not less than 2 times, or sequela is left;
fifthly, the patients with known allergy or dysphagia and can not take the medicine in the treatment.
The invention adopts the following method in the concrete implementation:
treatment 1 group was performed according to the traditional Chinese medicine clinical route of the State administration of traditional Chinese medicine, including rehabilitation training, at the recovery stage of stroke or cerebral infarction. In particular to 100mg of conventional oral aspirin bailey and 20mg of atorvastatin calcium tablet for 1 time/day; 100mL of ozagrel sodium chloride injection for intravenous injection, 20mL of danhong injection and citicoline injection.
Wherein the bessemeline is produced by Bayer medicine health care Limited company, and is provided with a Chinese medicine standard J20130078;
the atorvastatin calcium tablet is produced by a Hurrill pharmaceutical company Limited and has a national drug standard H20051407;
the ozagrel sodium chloride injection is produced by Shandong Hualu pharmaceutical Co., Ltd, and has the national standard character H20052059;
the Danhong injection is produced by Shandong Danhong pharmaceutical Co Ltd, and has the Chinese medicine standard Z20026866;
the citicoline injection is produced by Jilin century hanke pharmaceutical Co., Ltd, and is provided with the national standard character H22026208.
The treatment 2 group is treated by adding a thrombus clearing capsule on the basis of the treatment 1 group, wherein the capsule is produced by the second traditional Chinese medicine hospital in Shenyang city, has the batch number of Z20150797, is 0.34 g/capsule, is 6 capsules/time, is orally taken for 3 times/day, and is treated for 14 days.
The observation indexes and the judgment standards are as follows:
the results of the observation and comparison of the NIHSS score before and after treatment, the mRS score after treatment and the clinical efficacy of the two groups of patients were obtained.
The NIH SS score was: NIHSS is the stroke scale of national institutes of health, and is a commonly used evaluation scale for stroke.
The mRS score is: mRS is a modified Rankin score used to measure the outcome of functional recovery after a patient has had a stroke.
The therapeutic effect judgment standard is as follows: the reduction of the integral of symptoms after treatment is larger than or equal to 90 percent, and the symptoms are cured; the integral of the syndrome after treatment is reduced by 70 to 89 percent, which is the obvious effect; the reduction of the score of the syndrome after treatment by 30 to 69 percent is effective; a < 30% reduction in the score of the syndrome after treatment was not effective. The total effective rate is (cure + significant effect + effective)/total number of cases is multiplied by 100%.
The statistical diagnosis results are as follows:
(1) the results of the NIHSS and mRS scores were compared in two groups of patients:
the comparison of the NIHSS scores of the two groups of patients before treatment was not statistically significant (P > 0.05); after treatment, NIHSS scores were significantly lower in treatment 2 than in treatment 1, and the differences were statistically significant. After treatment, mRS score ≦ 1 for treatment 2 group was 18 cases, more than 11 cases for treatment 1 group, with statistically significant differences, see table 2.
TABLE 2 NIHSS score and mRS score comparison of two groups of patients: (
N)
Note: compared with the treatment group 1, the treatment group,*P<0.05 indicated significant differences.
(2) Clinical efficacy of two groups of patients was compared:
after 14 days of treatment, the total effective rate of the treatment group 2 is 96.7 percent, which is obviously higher than 80.0 percent of the treatment group 1, and the difference has statistical significance, which is shown in table 3.
TABLE 3 comparison of clinical efficacy of two groups of patients (n,%)
Note: compared with the treatment group 1, the treatment group,*P<0.05 indicated significant differences.
The traditional Chinese medicine raw materials selected by the invention have no toxic or side effect.
Example 6
The invention relates to a traditional Chinese medicine for treating ischemic stroke, which is applied to the technical field of treatment of patients with ischemic stroke, and the total effective rate of the treatment effect on patients with cerebral ischemia-reperfusion injury reaches 96.7 percent.
Although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope of the invention.
Claims (10)
1. A traditional Chinese medicine for treating cerebral arterial thrombosis is characterized in that: the health-care food is prepared from the following raw materials in parts by weight:
leech: ligusticum wallichii: arisaema cum bile = (10-15): (1-3): (0.5-1.5).
2. The traditional Chinese medicine for treating ischemic stroke as claimed in claim 1, which is characterized in that: the health-care food is prepared from the following raw materials in parts by weight:
leech: ligusticum wallichii: arisaema cum bile = 12: 2: 1.
3. the traditional Chinese medicine for treating ischemic stroke as claimed in claim 1, which is characterized in that: the health-care food is prepared from the following raw materials in parts by weight:
leech: ligusticum wallichii: arisaema cum bile = 10: 3: 1.5.
4. the traditional Chinese medicine for treating ischemic stroke as claimed in claim 1, which is characterized in that: the health-care food is prepared from the following raw materials in parts by weight:
leech: ligusticum wallichii: arisaema cum bile = 15: 1: 0.5.
5. the preparation method of the traditional Chinese medicine for treating ischemic stroke as claimed in claim 1, wherein the preparation method comprises the following steps: the method comprises the following steps:
step 1, taking the raw material leech according to the weight part ratio, cleaning, scalding, crushing and sieving for later use;
the leech scalding process comprises the following steps: placing pulvis Talci in a pan, parching with strong fire at 150-200 deg.C for 8-10min to flexible state, adding Hirudo, stirring, scalding at 150-200 deg.C for 5-10min until slightly swelling, taking out, sieving to remove pulvis Talci, and cooling;
step 2, taking the raw material of the ligusticum wallichii according to the weight part ratio, crushing, and sieving by a 80-200 mesh sieve for later use;
step 3, taking the raw material arisaema cum bile according to the weight part ratio, crushing, and sieving by a 80-200 mesh sieve for later use;
step 4, mixing the raw material powder obtained in the steps 1-3 according to the ratio of (10-15): (1-3): (0.5-1.5), sieving, granulating, drying, grading, and making into capsule.
6. The preparation method of the traditional Chinese medicine for treating ischemic stroke as claimed in claim 1, wherein the preparation method comprises the following steps: the leech scalding process comprises the following steps: firstly, scalding Hirudo at 170 deg.C for 8min, and pulverizing with rhizoma Ligustici Chuanxiong and rhizoma arisaematis cum bile into fine powder; and then taking the raw material medicinal powder of 12 parts of the scalding leech, 2 parts of the ligusticum wallichii and 1 part of the arisaema cum bile according to the weight part ratio, granulating, drying, finishing granules and filling into capsules to obtain the medicine.
7. The preparation method of the traditional Chinese medicine for treating ischemic stroke as claimed in claim 1, wherein the preparation method comprises the following steps: the leech scalding process comprises the following steps: firstly, scalding leech into a qualified product, and crushing the qualified product and the other two medicines into fine powder; and then taking 10 parts of leech, 3 parts of ligusticum wallichii and 1.5 parts of arisaema cum bile according to the weight part ratio, granulating, drying, finishing granules and encapsulating to obtain the capsule.
8. The preparation method of the traditional Chinese medicine for treating ischemic stroke as claimed in claim 1, wherein the preparation method comprises the following steps: the leech scalding process comprises the following steps: firstly, scalding leech into a qualified product, and crushing the qualified product and the other two medicines into fine powder; taking raw material medicinal powder of 15 parts of scalding leech, 1 part of ligusticum wallichii and 0.5 part of arisaema cum bile according to the weight part ratio, granulating, drying, finishing granules and filling into capsules to obtain the medicine.
9. A Chinese medicinal composition for treating ischemic stroke is used for treating ischemic stroke.
10. A Chinese medicinal composition for treating ischemic stroke is used for treating cerebral ischemia reperfusion injury.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010445451.1A CN111544501A (en) | 2020-05-24 | 2020-05-24 | Traditional Chinese medicine for treating cerebral arterial thrombosis and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010445451.1A CN111544501A (en) | 2020-05-24 | 2020-05-24 | Traditional Chinese medicine for treating cerebral arterial thrombosis and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111544501A true CN111544501A (en) | 2020-08-18 |
Family
ID=71996984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010445451.1A Pending CN111544501A (en) | 2020-05-24 | 2020-05-24 | Traditional Chinese medicine for treating cerebral arterial thrombosis and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111544501A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114617939A (en) * | 2021-12-31 | 2022-06-14 | 辽宁省血栓病中西医结合医疗中心 | Traditional Chinese medicine preparation for treating cerebral arterial thrombosis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101244234A (en) * | 2007-02-13 | 2008-08-20 | 广州安健实业发展有限公司 | Medicaments for preventing and controlling ischemia and hemorrhagic cerebrovaseular disease, and preparation thereof |
-
2020
- 2020-05-24 CN CN202010445451.1A patent/CN111544501A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101244234A (en) * | 2007-02-13 | 2008-08-20 | 广州安健实业发展有限公司 | Medicaments for preventing and controlling ischemia and hemorrhagic cerebrovaseular disease, and preparation thereof |
Non-Patent Citations (2)
| Title |
|---|
| 孙咏梅: "通栓胶囊干预风痰闭阻型中风恢复期患者的药物观察", 《中国实用医药》 * |
| 贺东辉，等: "川芎龙蛭汤联合尿激酶溶栓治疗急性脑梗死的临床研究", 《中西医结合心脑血管病杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114617939A (en) * | 2021-12-31 | 2022-06-14 | 辽宁省血栓病中西医结合医疗中心 | Traditional Chinese medicine preparation for treating cerebral arterial thrombosis |
| CN114617939B (en) * | 2021-12-31 | 2023-08-15 | 辽宁省血栓病中西医结合医疗中心 | Traditional Chinese medicine preparation for treating ischemic cerebral apoplexy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1051237C (en) | Meicinal prepn. "Kexianling" for curing epilepsy | |
| CN1628760A (en) | Traditional Chinese medicinal formulation for treating cardiovascular and cerebrovascular disease | |
| CN100586458C (en) | Medicine for treating cerebral apoplexy | |
| CN106729580A (en) | Treat the Chinese medicine of apoplexy at acute stage | |
| CN103623280B (en) | A kind of Chinese medicine preparation for the treatment of cardiovascular and cerebrovascular disease | |
| CN105663656A (en) | Pharmaceutical composition for treating sleep disorders and preparing method thereof | |
| CN111544501A (en) | Traditional Chinese medicine for treating cerebral arterial thrombosis and application | |
| CN103417716B (en) | Hypoglycemic Tongluo tablet for treating diabetic peripheral neuropathy | |
| CN102743455B (en) | Chinese patent medicine for treating diabetes mellitus | |
| CN104740208A (en) | Traditional Chinese medicine preparation for treatment of prosopalgia and preparation method thereof | |
| CN101474388B (en) | Improved prescription of Xianchan tablet medicament and preparation method thereof | |
| CN102139005B (en) | Medicine for treating cardiovascular and cerebrovascular diseases | |
| CN103127415B (en) | Traditional Chinese medicine for treating post-stroke limb numbness | |
| CN1111054C (en) | Medicine for treating apoplexy and its preparing process | |
| CN101549057A (en) | Chinese medicine composition for curing hyperlipemia, cerebral arteriosclerosis and ischemic apoplexy and method of preparing the same | |
| US20190167731A1 (en) | Traditional Chinese Medicine Composition for Treating Acute Stage of Cerebral Infarction | |
| CN101099836B (en) | Traditional Chinese medicine composition for treating ischemic apoplexy and preparation process thereof | |
| CN113117017A (en) | A Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases, and its preparation method | |
| CN104338052A (en) | Formula of traditional Chinese medicine for treating cerebral thrombosis | |
| CN115837065B (en) | Traditional Chinese medicine composition and application thereof | |
| CN114272329B (en) | Traditional Chinese medicine composition for treating liver and kidney deficiency type cervical spondylosis, preparation and application | |
| CN114617939B (en) | Traditional Chinese medicine preparation for treating ischemic cerebral apoplexy | |
| CN114306549B (en) | Traditional Chinese medicine composition for improving joint movement function after hip replacement surgery and relieving postoperative pain, preparation and application | |
| CN102225132A (en) | Traditional Chinese medicine compound for treating hyperlipidaemia, cerebral arteriosclerosis and ischemic stroke and preparation method thereof | |
| CN105770520A (en) | Medicine preparation used for treating coronary heart disease and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200818 |